GOCO: Lower Earnings Multiple Will Support Upside Despite Nasdaq Compliance Risk

Analysts cut their GoHealth price target from $7.70 to $4.70 as they factor in updated assumptions for revenue growth and margins, and incorporate the recent downgrade at Freedom Broker into their outlook.

Analyst Commentary

Bullish Takeaways

Bullish analysts view the reset to a US$4.70 target as a cleaner entry point that better reflects current expectations for revenue growth and margins, which they see as more achievable under updated assumptions.
Some see the stock as more fairly aligned with execution risk after factoring in the recent downgrade, and they argue that a lower target embeds a wider margin of safety if management delivers on operating goals.
Supporters highlight that the revised framework could reduce the risk of future estimate cuts, which may help valuation stabilize if GoHealth meets or modestly exceeds the new baseline.
Bullish analysts also point out that a tighter focus on profitability metrics in the new outlook can help investors track whether management is moving in the right direction on cost control and unit economics.

Bearish Takeaways

Bearish analysts see the move down from US$7.70 to US$4.70 as a sign that previous expectations for revenue growth and margins were too optimistic, and in their view this raises questions about forecast reliability.
The recent downgrade is taken by some as a signal that execution risk remains elevated, especially around delivering consistent margin performance in a competitive health insurance distribution market.
More cautious voices argue that even with a lower target, the stock may still rely on smooth execution to justify its valuation, leaving limited room for operational missteps.
There is also concern that further revisions could be needed if the updated assumptions on growth or profitability prove aggressive, which could weigh on investor confidence in the near term.

What's in the News

Nasdaq notified GoHealth on March 18, 2026 that the company is not in compliance with the Nasdaq Global Market minimum market value of listed securities requirement of US$35 million under Listing Rule 5550(b)(2) (Key Developments).
The notice also states that GoHealth does not meet alternative continued listing standards that call for at least US$2.5 million in stockholders' equity or net income from continuing operations of US$500,000 in the most recent fiscal year or two of the last three fiscal years (Key Developments).
GoHealth has a 180 day compliance period ending September 14, 2026 to regain compliance. Nasdaq may confirm compliance if the company maintains a market value of listed securities at or above US$35 million for at least 10 consecutive business days, and potentially up to 20 business days at Nasdaq's discretion (Key Developments).
The notice has no immediate effect on trading, and GoHealth's common stock continues to trade on the Nasdaq Global Market under the ticker GOCO while the company evaluates options to regain compliance. There is no assurance it will meet the listing requirements (Key Developments).
If GoHealth does not regain compliance within the specified period, Nasdaq is expected to issue a delisting notice. The company would have the opportunity to appeal to a Nasdaq Hearings Panel, which would temporarily stay any suspension or delisting action during the hearing process (Key Developments).

Valuation Changes

Fair Value: The analyst fair value estimate shifted from $7.70 to $4.70, a reduction that brings the target closer to the recent reset discussed earlier.
Discount Rate: The discount rate remains unchanged at 12.33%, indicating that the analysts are keeping the same required return for assessing GoHealth's equity risk.
Revenue Growth: Revenue growth assumptions moved from a 10.75% decline to 14.56% growth, reflecting a swing in expectations toward revenue expansion rather than contraction.
Net Profit Margin: Net profit margin estimates are broadly stable, moving slightly from 11.18% to 11.20%, which keeps profitability assumptions almost the same.
Future P/E: The future P/E multiple moved from 3.53x to 2.08x, indicating that the updated model applies a lower earnings multiple to GoHealth's projected results.

0 views

Key Takeaways

Improved financial flexibility and strategic focus enable investment in technology, product expansion, and acquisitions, supporting future revenue growth and margin improvement.
Diversification into life insurance and enhanced tech capabilities boost efficiency, reduce earnings volatility, and position the company to capture greater market share.
Heavy reliance on debt, share dilution, and challenging acquisitions amid regulatory and market uncertainty heighten risks to sustainable growth and long-term value stability.

Catalysts

About GoHealth

Operates as a health insurance marketplace and Medicare-focused digital health company in the United States.What are the underlying business or industry changes driving this perspective?

The newly secured $115 million term loan facility, along with covenant relief and maturity extensions, grants GoHealth significant financial flexibility and removes immediate going concern issues, enabling proactive investment in technology, product growth, and M&A-positioning the company for revenue growth and improved net margins over the medium term.
The company's ability to actively pursue strategic acquisitions in a fragmented Medicare and senior health marketplace-with up to $250 million of lender-approved deal capacity and an empowered Transformation Committee-positions GoHealth to capture greater market share and drive scale-driven operating leverage, benefitting both revenue and margins.
Deployment and scaling of the GoHealth Protect (final expense/life insurance) product suite diversifies revenue sources beyond Medicare Advantage, reducing earnings volatility and creating new cross-sell opportunities-expected to support incremental revenue growth and margin stabilization as the digitalization of healthcare shopping accelerates.
Enhanced technology and data-driven supply/demand matching are enabling higher agent productivity and operational efficiency, which should allow for lower cost per acquisition and higher lead-to-policy conversion rates-supporting future earnings and margin expansion as consumer reliance on advisory platforms increases due to rising healthcare complexity.
GoHealth remains structurally levered to ongoing demographic aging and heightened regulatory/benefit disruption in core Medicare markets, creating sustained demand for unbiased, tech-enabled plan selection platforms-likely to translate into persistent customer acquisition opportunities and long-term top-line growth.

GoHealth Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming GoHealth's revenue will grow by 14.6% annually over the next 3 years.
Analysts are not forecasting that GoHealth will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate GoHealth's profit margin will increase from -72.1% to the average US Insurance industry of 11.2% in 3 years.
If GoHealth's profit margin were to converge on the industry average, you could expect earnings to reach $60.9 million (and earnings per share of $3.07) by about April 2029, up from -$261.1 million today.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 2.2x on those 2029 earnings, up from -0.1x today. This future PE is lower than the current PE for the US Insurance industry at 11.5x.
Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 12.33%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

GoHealth's recent issuance of significant equity to lenders as part of the new debt facility leads to share dilution, directly impacting per-share earnings and potentially limiting share price appreciation for existing shareholders despite operational improvements.
The company is undergoing an intangible asset impairment, indicative of prior overvaluation of assets or underperformance in acquired businesses; this raises concerns over GoHealth's ability to accurately forecast and deliver sustained value from acquisitions, increasing volatility and uncertainty in long-term earnings and revenue streams.
While GoHealth has secured a temporary covenant holiday and capital runway, its reliance on debt financing with high interest rates (SOFR + 550 bps) raises longer-term financial risk and higher interest expenses, which can compress net margins and reduce future profitability.
GoHealth's strategy to focus more intensely on industry consolidation and M&A, while potentially accretive, exposes it to substantial execution risk and integration challenges-if acquisitions fail to deliver expected synergies or results, this could hinder revenue growth and margin expansion.
The company's substantial pullback from Medicare Advantage activity in response to health plan uncertainty, along with ongoing regulatory and market disruptions, highlights its sensitivity to external factors (like plan benefit changes and regulatory shifts), which could further impact customer acquisition, retention, and revenue predictability going forward.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $4.7 for GoHealth based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $10.0, and the most bearish reporting a price target of just $1.5.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $544.0 million, earnings will come to $60.9 million, and it would be trading on a PE ratio of 2.2x, assuming you use a discount rate of 12.3%.
Given the current share price of $1.09, the analyst price target of $4.7 is 76.8% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on GoHealth?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Financial Flexibility And M&A Will Unlock Medicare And Senior Health Potential